GLP-1 Shortage Update 2026: What's Available and Your Options
Current status of Ozempic, Wegovy, Mounjaro, and Zepbound availability in 2026. What the shortage means for compounded semaglutide and how to maintain your treatment.
More on GLP-1 Access & Supply
Compounded Semaglutide vs Wegovy
Is compounded semaglutide the same as Wegovy?
FDA Compounding Exemption 2026
The legal framework for compounded GLP-1 medications.
Cheapest GLP-1 Injections 2026
All the low-cost access options ranked.
Semaglutide Savings Programs
Manufacturer coupons and assistance programs.
Last Updated: April 2026
GLP-1 supply status changes frequently. This article reflects the most current information available as of April 2026. Check with your provider or pharmacy for real-time availability.
Current Supply Status by Drug (April 2026)
Semaglutide (Wegovy/Ozempic)
Generally availableSupply improved significantly; some regional gaps remain at individual pharmacies.
Tirzepatide (Zepbound/Mounjaro)
Generally availableAvailability has normalized for most doses. Higher doses (12.5mg, 15mg) may still have wait times at some pharmacies.
Compounded Semaglutide
Available through telehealth programsShortage-based compounding pathway closed, but 503A/503B pathways remain. Reputable providers like Trimi continue operations.
Compounded Tirzepatide
Available through telehealth programsSimilar to semaglutide — shortage pathway closed but other compounding routes remain viable.
The Timeline: How We Got Here
Why Demand Still Outpaces Access
Even with improved supply, access barriers remain significant. The core issue isn't manufacturing capacity anymore — it's price. With brand-name Wegovy at ~$1,349/month and Zepbound at ~$1,059/month, most Americans cannot afford these medications out-of-pocket. Insurance coverage remains uneven: many commercial plans don't cover obesity medications, Medicare only recently began covering them for specific cardiovascular indications, and state Medicaid coverage varies enormously.
This economic access gap is what continues to drive demand for compounded GLP-1 medications. Even after the FDA shortage list removal, millions of patients cannot access brand-name drugs and rely on compounding as their only affordable pathway. See our cheapest GLP-1 injections guide for all current options.
Your Options If You Can't Get Brand-Name GLP-1
- 1. Compounded semaglutide through telehealth: Legal under 503A/503B, same active molecule, ~70–80% cost reduction. Trimi's program includes physician oversight and ships directly to your door. See how it works.
- 2. Manufacturer savings programs: Novo Nordisk's NovoCare and Eli Lilly's Lilly Cares programs offer reduced pricing for qualifying uninsured patients. See our savings programs guide.
- 3. Insurance appeals: If initially denied, appeal with documentation of comorbidities. Success rates have improved as obesity gains recognition as a chronic disease. See our insurance denial appeal guide.
- 4. HSA/FSA: Some GLP-1 prescriptions may qualify for HSA/FSA spending depending on the approved indication and your plan. Check with your benefits administrator.
- 5. Switch medications: If one drug is unavailable or too expensive, discuss with your provider whether switching from semaglutide to tirzepatide or vice versa is appropriate.
Compounding After the Shortage List: What's Legal in 2026
The FDA's removal of semaglutide from the shortage list does not make compounding illegal. It removes one specific legal pathway (shortage-based compounding under Section 503B). Other pathways remain intact:
- 503A compounding: Patient-specific prescriptions from licensed pharmacies — legal regardless of shortage status
- 503B outsourcing facilities: Can continue operating under their own compliance frameworks and specific qualifying criteria
- Customization argument: Compounding different strengths, combinations, or delivery methods that aren't available commercially remains legally viable
For a full analysis of the legal framework, see our dedicated article on FDA compounding regulations and exemptions in 2026.
Frequently Asked Questions
Is there still a GLP-1 shortage in 2026?
The shortage landscape has shifted significantly. The FDA officially removed semaglutide (Wegovy/Ozempic) from the drug shortage list in early 2025, declaring adequate supply. Tirzepatide (Zepbound/Mounjaro) has also seen improved availability, though regional and pharmacy-level shortages persist. Demand continues to grow faster than manufacturing capacity in some markets.
Can I still get compounded semaglutide in 2026?
Yes, but with important nuances. When semaglutide was removed from the FDA shortage list, it changed the legal basis for shortage-based compounding. However, compounding pharmacies can still produce semaglutide under Section 503A (patient-specific) and 503B (outsourcing facility) pathways that don't require shortage status. Many telehealth providers, including Trimi, continue to offer compounded semaglutide legally.
What should I do if my pharmacy can't fill my Wegovy prescription?
Options include: asking your provider to switch to a compounded semaglutide program, requesting a prior authorization for tirzepatide if Wegovy is unavailable, checking multiple pharmacies and specialty pharmacy networks, or temporarily switching to oral semaglutide if appropriate. Don't abruptly stop GLP-1 therapy without medical guidance.
How has the shortage affected pricing?
Brand-name pricing has remained high ($900–$1,349/month) regardless of shortage status. Compounded semaglutide pricing has remained significantly lower ($200–$400/month). The legal shift post-shortage list removal has not materially impacted pricing at reputable telehealth providers.
Will brand-name GLP-1 drugs get cheaper in 2026?
Brand-name prices have not dropped significantly in 2026. Novo Nordisk and Eli Lilly continue to list Wegovy and Zepbound at $900–$1,300/month. Patent protection prevents generic competition until approximately 2031–2032 for semaglutide. Continued pressure from compounders and insulin-pricing precedent may drive negotiated pricing changes with insurers.